Washington, D.C. 20549




Current Report

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): July 22, 2019



(Exact name of registrant as specified in its charter)


England and Wales




Not Applicable

(State or other jurisdiction of


(Commission File Number)


(IRS Employer Identification No.)


60 Jubilee Avenue, Milton Park

Abingdon, Oxfordshire OX14 4RX

United Kingdom

(Address of principal executive offices, including zip code)


(44) 1235 430000

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o                        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o                        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o                        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o                        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company o


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Securities registered pursuant to Section 12(b) of the Act:


Title of each class


Trading Symbol


Name of each exchange on which

American Depositary Shares, each representing 6 Ordinary Shares, par value £0.001 per share




The Nasdaq Global Select Market





Item 8.01                                           Other Events.


On July 22, 2019, Adaptimmune Therapeutics plc issued a press release announcing that it has initiated a radiation sub-study of its ADP-A2M4 trial in collaboration with the University of Texas MD Anderson Cancer Center in Houston, TX. The press release is furnished as Exhibit 99.1 to this report and is incorporated by reference herein.


Item 9.01                                           Financial Statements and Exhibits.


(d)  Exhibits.


Exhibit No.


Description of Exhibit






Press release dated July 22, 2019.






Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.











Date: July 22, 2019


/s/ Margaret Henry




Margaret Henry




Corporate Secretary



Exhibit 99.1



Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center


- Compelling responses previously reported with ADP-A2M4 in sarcoma -


- Use of low-dose radiation intended to enhance antitumor activity -


PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 22, 2019 — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has initiated a radiation sub-study of its ADP-A2M4 trial in collaboration with the University of Texas MD Anderson Cancer Center in Houston, TX. Published data indicate that low-dose radiation has the potential to enhance T-cell responses in the context of solid tumors.(1)


“We have seen compelling data in sarcoma with ADP-A2M4 SPEAR T-cells and will initiate our SPEARHEAD-1 trial for sarcoma patients later this year. In addition, we are eager to increase the depth and durability of the antitumor activity that we have observed in other solid tumors with ADP-A2M4,” said Rafael Amado, Adaptimmune’s President of R&D. “There is emerging data showing that low-dose radiation could enhance T-cell tumor trafficking and responses. We are looking forward to the results of this radiation sub-study with ADP-A2M4.”


The radiation sub-study is planned to enroll 10 patients across multiple solid tumor indications. Patients will receive low-dose radiation in up to 5 lesions prior to treatment with ADP-A2M4, at target doses of 1 to 10 billion SPEAR T-cells. The lymphodepletion regimen will be fludarabine (30 mg/m2/day) for 4 days and cyclophosphamide (600 mg/m2/day) for 3 days.


Adaptimmune and the MD Anderson Cancer Center have a multi-year strategic alliance designed to expedite the development of novel adoptive T-cell therapies for multiple types of cancer.


About Adaptimmune


Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for cancer patients. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. For more information, please visit http://www.adaptimmune.com.


Forward-Looking Statements


This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 6, 2019, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.


(1)  *Barsoumian, 2018; DeSelm, 2018




Adaptimmune Contacts:


Media Relations:

Sébastien Desprez — VP, Communications and Investor Relations

T: +44 1235 430 583

M: +44 7718 453 176



Investor Relations:

Juli P. Miller, Ph.D. — Senior Director, Investor Relations

T: +1 215 825 9310

M: +1 215 460 8920